Alumni Profile: Scott Greenhalgh

Scott GreenhalghScott Greenhalgh (MSc in Evidence-Based Social Intervention and Policy Evaluation, 2015) is a social impact investor. He believes in both the responsibility and power of business to contribute positively to social and environmental challenges.

Scott is currently working with a number of mission-driven entrepreneurs to help grow their businesses and deliver greater positive social impact. He was formerly Executive Chairman of Bridges Evergreen, the UK’s first long-term investment vehicle for social impact investing and led this fund from inception until earlier this year. His background is in private equity.

Scott is a former England Committee member of the Big Lottery Fund (now National Lottery Community Fund) where he oversaw A Better Start, a £210m grant programme focused on tackling disadvantage in the early years.

He chaired the Royal Foundation’s Early Years Steering Group on behalf of HRH The Duchess of Cambridge. He is a Trustee of the London Community Foundation and Outside In.

Contact: esgreenhalgh@gmail.com


The Radcliffe Observatory has stood for over 250 years.

But heritage requires care and the building now needs restoration to preserve it for future generations.

Support this work by joining the Radcliffe 100 and the Radcliffe 250. 

Find out more via the link in our bio 💫
🦖🦴 Major archaeological discovery at the Radcliffe Observatory 🦖🦴

What began as routine landscaping work on the front lawn has taken a rather unexpected turn…

Earlier this week, contractors uncovered what appear to be dinosaur bones.

Initial (very enthusiastic) assessments suggest the remains could belong to a previously unknown species, tentatively named Green Templetonosaurus.

We’ll share further updates as soon as we know more… 🦖
When the researcher becomes the patient.

In this thought-provoking reflection for The Times Magazine, Research Fellow Karl Smith Byrne shares what tackling cancer has taught him both in his work and in his own life.

Diagnosed with rectal cancer at just 27, Karl brings a rare dual perspective to his field, combining research with lived experience to advocate for greater focus on prevention and more patient-centred science.

A compelling insight into resilience and the future of cancer research.
FOLLOW ON INSTAGRAM